Estrella Immunopharma, Inc. (ESLA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-94.4%

$0.02

vs $0.43 price

Levered DCF

$0.04

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-52.49

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
P/E	-4.46×	-5×	-5.24×	-32.16×	-206.89×	-468.75×
P/B	-5.54×	306.25×	9.06×	51.23×	-335.48×	0×
P/S	0×	0×	0×	0×	0×	0×
EV / EBITDA	-4.29×	-4.87×	-4.73×	-32.63×	-204.56×	0×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	0.12×	0.55×	24.65×	0.05×	5.2×	0×
Debt / equity	0×	0×	0×	0.07×	0×	0×
Interest coverage	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Return on equity	126.0%	-6155.7%	-171.1%	-157.2%	162.1%	0.0%
Return on invested capital	126.0%	-6154.5%	-51.5%	-118.1%	-3.4%	0.0%
Return on assets	-411.2%	-281.7%	-164.2%	-111.3%	-34.2%	0.0%
Free cash flow yield	-3.1%	-7.1%	-41.5%	-0.3%	-0.4%	-0.2%
Earnings yield	-22.7%	-20.1%	-18.9%	-3.1%	-0.5%	-0.2%
Enterprise value	$56.1M	$43.1M	$34.6M	$362.7M	$344.8M	$0
Net debt / EBITDA	0.11×	0.1×	0.57×	-0.04×	2.43×	0×
Cash conversion cycle (days)	0	0	0	0	0	0